50.0% of participants treated with leronlimab demo

Quote:

---

50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223).

---

Yes, and day 14 was (if I remember correctly) a week after the second and final injection of Leronlimab. So after this the patients' bodies effectively cleared the Leron, and two weeks later, at the final endpoint of the trial, they were effectively no longer being treated. Thanks to the FDA insistence that there only be two Leron treatments, the Covid trials failed.